Analyst firms · The Benchmark Company · ABCL

The Benchmark Company ABCL price target and rating history

AbCellera Biologics Inc. (ABCL) · Health Care

The Benchmark Company rates AbCellera Biologics Inc. (ABCL) Buy with a $11 price target, as of its latest action on Jul 7, 2026. It has published 6 rating actions on ABCL since December 2021, including 2 upgrades and 2 downgrades. Across 5 firms with a ABCL price target in the last 12 months, the median target is $13. The Benchmark Company's $11 is 15% below that.

Current rating
Buy
Price target
$11
Median target, all firms
$13
Actions on ABCL
6

The Benchmark Company price target on ABCL

$27$18$920222023202420252026
The Benchmark Company price target on ABCL, each point a stated target, December 2021 to July 2026.

Every The Benchmark Company rating on ABCL

How other firms rate ABCL

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Lake StreetBuy$19Nov 18, 2026
UBSBuy$18Oct 12, 2026
Goldman SachsNeutral$13Sep 24, 2026
The Benchmark CompanyBuy$11Jul 7, 2026
Cantor FitzgeraldOverweight$7May 5, 2026

Questions about The Benchmark Company and ABCL

What is The Benchmark Company's price target for ABCL?
The Benchmark Company's latest stated price target for AbCellera Biologics Inc. (ABCL) is $11, from its action on Jul 7, 2026.
What is The Benchmark Company's rating on ABCL?
The Benchmark Company rates ABCL Buy, a bullish rating, as of Jul 7, 2026.
When did The Benchmark Company last change its view on ABCL?
On Jul 7, 2026, The Benchmark Company upgrades to Buy from Hold, price target $11.
How does The Benchmark Company's ABCL target compare with other analysts?
Across 5 firms with a ABCL price target in the last 12 months, the median target is $13. The Benchmark Company's $11 is 15% below that.

More ABCL rating histories

All The Benchmark Company ratingsABCL news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.